A5087711816- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Cardiac Valve Diseases and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Acute Myocardial Infarction Research
- Cardiac Structural Anomalies and Repair
- Cancer Immunotherapy and Biomarkers
- Infective Endocarditis Diagnosis and Management
- Influenza Virus Research Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular Disease and Adiposity
- Transplantation: Methods and Outcomes
- Chronic Myeloid Leukemia Treatments
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac tumors and thrombi
- PARP inhibition in cancer therapy
- Biomarkers in Disease Mechanisms
- Cerebrovascular and Carotid Artery Diseases
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Cardiovascular Function and Risk Factors
- Cancer Treatment and Pharmacology
- Neurological disorders and treatments
- Takotsubo Cardiomyopathy and Associated Phenomena
Monash University
2020-2025
Monash Health
2016-2025
Australian Centre for Heart Health
2021-2024
Victorian Heart Hospital
2023-2024
Monash Medical Centre
2014-2023
New York Institute of Technology
2022
Baker Heart and Diabetes Institute
2022
Bendigo Health
2022
The University of Texas Southwestern Medical Center
2021
Peninsula Health
2021
Androgen deprivation therapy is the cornerstone of treatment for patients with advanced prostate cancer. Meta-analysis small, oncology-focused trials suggest gonadotropin-releasing hormone (GnRH) antagonists may be associated fewer adverse cardiovascular outcomes compared GnRH agonists.
A lack of geographic and racial diversity in clinical trial populations may arise from a disproportionate focus on the United States Europe for leadership conduct. Inadequate compromise external validity to Asia-Pacific (APAC) region, where 60% global cardiometabolic disease exists. This study aimed assess proportion trends Asian race participants APAC authorship trials. We performed systematic review all cardiovascular, diabetes obesity-related randomized controlled trials (phase ≥2, n =...
Background Preprocedural fasting is widely used before percutaneous coronary intervention (PCI). However, the incidence of procedural intubation during PCI unknown. This study aims to identify and predictors for PCI. Methods Results A retrospective cohort was performed on patients undergoing between 2014 2021 within Victorian Cardiac Outcomes Registry. Patients were classified into urgent, semiurgent, or elective basis recorded indication. Those semiurgent presumed be fasted preprocedurally....
Cardiovascular disease is the leading cause of non-cancer related mortality and morbidity among people living with or cured from cancer. Immune checkpoint inhibitors (ICIs) are systemic anti-cancer therapies that have revolutionised treatment numerous cancers, even achieving durable long-term responses patients metastatic disease. However, pro-inflammatory effects ICIs been postulated to increase risk atherosclerotic cardiovascular (ASCVD) in cancer survivorship. Standard modifiable factors...
Abstract Objectives Epicardial adipose tissue (EAT) is a proposed marker of cardiovascular risk; however, clinical application may be limited by variability in post-processing software platforms. We assessed inter-vendor agreement EAT volume (EATv) and attenuation on both contrast-enhanced (CE) non-contrast CT (NCT) using standard coronary reporting (Vitrea), an research-specific (QFAT) freeware imaging (OsiriX). Methods Seventy-six consecutive patients undergoing simultaneous CE NCT had...
Immunotherapy has become a pillar of modern oncological management but is associated with significant immunotherapy-related adverse events (IRAEs). While myocarditis prominent IRAE which clinicians are increasingly aware of, coronary vasospasm far less appreciated and can be especially difficult to elucidate in pre-existing artery disease. This case demonstrates the approach diagnosis multiple cardiovascular non-cardiovascular IRAEs.
Seasonal influenza immunisation reduces cardiovascular events in high-risk patients, but 50% do not receive routine immunisation. The perceptions and current role of cardiologists recommending prescribing has been well described.